Implementation of WHO Global Antimicrobial Resistance Surveillance System in Uganda: National Surveillance Report, 2015 to 2020 (Preprint)

2021 ◽  
Author(s):  
Susan Nabadda ◽  
Francis Kakooza ◽  
Reuben Kiggundu ◽  
Richard Walwema ◽  
Joel Bazira ◽  
...  

BACKGROUND Antimicrobial resistance is an emerging public health crisis in Uganda. The WHO Global Action Plan recommends that countries develop and implement National Actions Plans for AMR. We describe the establishment of the national AMR program in Uganda and present earlier sensitivity results from the program. OBJECTIVE The objective of the national surveillance programme is the systematic, continuous collection, analysis and interpretation of antimicrobial resistance data. METHODS A systematic qualitative description of the process and progress made in the establishment of the national AMR program is provided, detailing progress made since 2015 to 2020. This is followed with reporting of the findings of the isolates that are collected from the sentinel AMR surveillance sites. The identification and AST of bacterial isolates presented was done using standard methods at both the sentinel sites and the national reference laboratory. RESULTS Progress has been made in establishment of the national AMR program and implementation of the GLASS protocol is ongoing. A national coordinating centre and focal person have been established, a national reference laboratory has been designated, WHO net set up, sentinel AMR surveillance sites have been established with both data and laboratory quality assurance incorporated. Uganda has progressively submitted data to the GLASS reporting system. 19,216 isolates from WHO GLASS priority specimens were collected of which 22.95% (n=4,411) were community acquired infections (CAIs), 9.5% (n=1,818) had hospital acquired infections (HAIs) with 68.57% (n=12,987) being of unknown origin. The highest proportion of the specimens was blood (n=12,398, 64.5%) followed by urine (n=5,278, 27.5%), and then by stool (n=1,266, 6.6%), while, the least proportion were uro-genital swabs (n=274, 1.4%). The mean age was 19.1 (SD=19.8) years while the median was 13 (IQR: 28). Approximately 49.1% of the participants were female and 50.5% were male. Participants with CAIs were older than those with HAIs i.e. Mean: 28.0 (SD=18.6), Median: 26, IQR: 20.5 vs. Mean: 17.3 (SD=20.9) Median 8 IQR: 26. All gram-negative (E. coli, K. pneumoniae, N. gonorhoeae) and gram-positive (S. aureus, Enterococcus sp.) bacteria with AST done showed resistance to each of the tested antibiotics. CONCLUSIONS We demonstrate that systematic capacity building for implementation of the WHO GLASS protocol is feasible in a low resource setting. CLINICALTRIAL NA

2020 ◽  
Vol 25 (43) ◽  
Author(s):  
Cristina C Celma ◽  
Stuart Beard ◽  
Amy Douglas ◽  
Shan Wong ◽  
Nana-Kwame Osafo ◽  
...  

Background Rapid diagnostic tests are commonly used by hospital laboratories in England to detect rotavirus (RV), and results are used to inform clinical management and support national surveillance of the infant rotavirus immunisation programme since 2013. In 2017, the Public Health England (PHE) national reference laboratory for enteric viruses observed that the presence of RV could not be confirmed by PCR in a proportion of RV-positive samples referred for confirmatory detection. Aim We aimed to compare the positivity rate of detection methods used by hospital laboratories with the PHE confirmatory test rate. Methods Rotavirus specimens testing positive at local hospital laboratories were re-tested at the PHE national reference laboratory using a PCR test. Confirmatory results were compared to original results from the PHE laboratory information management system. Results Hospital laboratories screened 70.1% (2,608/3,721) of RV samples using immunochromatographic assay (IC) or rapid tests, 15.5% (578/3,721) using enzyme immunoassays (EIA) and 14.4% (535/3,721) using PCR. Overall, 1,011/3,721 (27.2%) locally RV-positive samples referred to PHE in 2016 and 2017 failed RV detection using the PHE reference laboratory PCR test. Confirmation rates were 66.9% (1,746/2,608) for the IC tests, 87.4% (505/578) for the EIA and 86.4% (465/535) for the PCR assays. Seasonal confirmation rate discrepancies were also evident for IC tests. Conclusions This report highlights high false positive rates with the most commonly used RV screening tests and emphasises the importance of implementing verified confirmatory tests for RV detections. This has implications for clinical diagnosis and national surveillance.


2007 ◽  
Vol 136 (3) ◽  
pp. 352-359 ◽  
Author(s):  
H. M. HEFFERNAN ◽  
D. R. MARTIN ◽  
R. E. WOODHOUSE ◽  
J. MORGAN ◽  
T. K. BLACKMORE

SUMMARYIsolates from 3903 cases of invasive pneumococcal disease (IPD) were referred to the national reference laboratory over the 8 years, 1998–2005, as part of the laboratory-based surveillance of this disease in New Zealand. All isolates were serotyped and their antimicrobial susceptibility was tested. The incidence of IPD was highest in young children, with an average annual incidence of 100·8/100 000 in infants aged <2 years. There were changes in the prevalence of several of the serotypes during the 8-year period. Overall the seven serotypes included in the 7-valent pneumococcal conjugate vaccine, 4, 6B, 9V, 14, 18C, 19F and 23F, were the most common serotypes and accounted for 80·9% of the disease in infants aged <2 years. There was no overall change in penicillin resistance or non-susceptibility during the 8 years, and rates were 7·1% and 17·1%, respectively, in 2005. In contrast, cefotaxime and erythromycin resistance increased to reach 3·1% and 12·2%, respectively, by 2005.


2018 ◽  
Vol 147 ◽  
Author(s):  
K. Mellou ◽  
E. Saranti-Papasaranti ◽  
G. Mandilara ◽  
T. Georgakopoulou

AbstractAusterity might have affected the capacity of public hospitals in Greece to diagnose salmonellosis (laboratory capacity) over the period 2010–2016, as well as the performance of the existing surveillance systems. The scope of this paper is to present data on laboratory capacity over these years, as well as the results of a two-source capture-recapture study (data from Mandatory Notification System and National Reference Laboratory System for Salmonella). The main findings were that: (a) laboratory capacity was high and steady besides the financial crisis, (b) the estimated number of laboratory-confirmed cases (n = 6017, 95% CI 5892–6142) resulted in an incidence rate (7.9 cases/100 000 population) almost twice than that reported by the two systems Mandatory Notification System (MNS); 4.1 and National Reference Laboratory System (NRLS); 4.5 cases/100 000 population, (c) underreporting was high for both systems (MNS; 47.5% and NRLS; 42.8%) and (d) differences by geographical region, size and type of hospital were identified. We suggest that (a) specific interventions are needed to increase completeness of the systems by type of hospital and geographical region, (b) record linkage can help in estimating the disease burden in a more valid way than each system separately and (c) a common electronic database in order to feed one system to the other could significantly increase completeness of both systems.


2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Çiğdem Karakükcü ◽  
Mehmet Zahid Çıracı ◽  
Derya Kocer ◽  
Mine Yüce Faydalı ◽  
Muhittin Abdulkadir Serdar

Abstract Objectives To obtain optimal immunoassay screening and LC-MS/MS confirmation cut-offs for opiate group tests to reduce false positive (FP) and false negative (FN) rates. Methods A total of 126 urine samples, −50 opiate screening negative, 76 positive according to the threshold of 300 ng/mL by CEDIA method – were confirmed by a full-validated in-house LC-MS/MS method. Sensitivity, specificity, FP, and FN rates were determined at cut-off concentrations of both 300 and 2,000 ng/mL for morphine and codeine, and 10 ng/mL for heroin metabolite 6-mono-acetyl-morphine (6-MAM). Results All CEDIA opiate negative urine samples were negative for morphine, codeine and 6-MAM. Although sensitivity was 100% for each cut-off; specificity was 54.9% at CEDIA cut-off 300 ng/mL vs. LC-MS/MS cut-off 300 ng/mL and, 75% at CEDIA cut-off 2,000 ng/mL vs. LC-MS/MS cut-off 2,000 ng/mL. False positive rate was highest (45.1%) at CEDIA cut-off 300 ng/mL. At CEDIA cut-off 2,000 ng/mL vs. LC-MS/MS cut-off 300 ng/mL, specificity increased to 82.4% and FP rate decreased to 17.6%. All 6-MAM positive samples had CEDIA concentration ≥2,000 ng/mL. Conclusions 2,000 ng/mL for screening and 300 ng/mL for confirmation cut-offs are the most efficient thresholds for the lowest rate of FP opiate results.


2012 ◽  
Vol 5 (1) ◽  
pp. 3 ◽  
Author(s):  
Arturo Anguiano ◽  
Boris T Wang ◽  
Shirong R Wang ◽  
Fatih Z Boyar ◽  
Loretta W Mahon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document